AAV Viral Vector (AAV) Packaging

1. Service Overview

Adeno-associated virus (AAV) is a member of the parvovirus family capable of infecting both dividing and non-dividing cells. It has emerged as one of the most promising viral vector systems for gene therapy and gene function research. AAV offers distinct advantages including a high safety profile, low immunogenicity, strong tissue tropism, and durable in vivo expression. It currently serves as the core vector platform for multiple FDA-approved gene therapy products.

Compared with other viral vectors, AAV offers several key advantages:

• Superior diffusivity: AAV is small in size and can be produced at high titers. Compared to adenoviruses and lentiviruses, it exhibits greater diffusivity and is capable of crossing the blood–brain barrier, making it the ideal tool for infecting the nervous system.

• High specificity: AAV encompasses multiple serotypes with distinct tissue recognition and infection profiles, making it the preferred vector for animal studies.

• High safety: AAV persists predominantly as extrachromosomal episomes, minimizing the risk of insertional mutagenesis. Its low immunogenicity makes it directly applicable to human gene therapy.

From Bench to Bedside: AAV Clinical Milestones

The clinical value of AAV has been validated by a growing portfolio of approved products. The market continues to expand rapidly, with indications broadening from rare genetic disorders to neurodegenerative diseases, cardiovascular conditions, and oncology—representing enormous commercial potential.

2. Service Offerings

GeneRulor provides a comprehensive suite of services spanning AAV plasmid design, construction, packaging, and expression analysis. In addition, we offer a full range of AAV vectors and expression systems for in vivo and in vitro expression of human/mouse/rat ORFs, lncRNAs, circRNAs, shRNAs, and CRISPR/gRNA constructs. Our AAV products are characterized by three hallmarks of quality: high titer, high purity, and high stability. The de novo AAV production workflow is illustrated below.

Fig1. AAV Production Workflow Schematic

3. AAV Serotype Selection Guide

The tissue tropism of AAV is determined by its capsid protein. Selecting the correct serotype is critical for experimental success. Shutong Biotechnology covers AAV1–9, AAV-DJ, and a range of engineered serotypes. Refer to the selection guide below:

4. Service Packages & Specifications

5. Service Highlights

• Comprehensive vector portfolio: A wide selection of tissue-specific promoters and reporter genes is available to meet diverse experimental needs.

• Fast turnaround: Our AAV cloning vectors are universally compatible with the MCS region of our library of 18,000 pre-made human ORF cDNA clones, enabling one of the shortest production cycles in the industry.

• High titer: We routinely deliver viral titers of ≥10¹² VG/mL, with the capability to reach up to 10¹⁴ VG/mL.

• Customized expertise: Our technical specialists provide tailored vector design and construction strategies based on each client’s specific experimental requirements.

6. Frequently Asked Questions (FAQs)

Q1: How do I select the appropriate AAV serotype?

The primary consideration is the target organ, followed by the route of administration and animal model (mouse vs. NHP):

• Central nervous system (CNS): AAV9 (intravenous delivery), AAV-PHP.eB (broad CNS distribution in mice)

• Liver: AAV8

• Skeletal muscle / myocardium: AAV1, AAV6, AAV9

• Retina: AAV2 (intravitreal), AAV5 (subretinal)

If the target tissue is uncertain, we recommend pre-screening with AAV-DJ in vitro. Our technical team can provide customized serotype recommendations based on your specific animal model.

Q2: How is AAV titer measured at GeneRulor?

We primarily use quantitative PCR (qPCR) to determine genomic titer (genome copies, GC/mL). Primers are designed against ITR sequences or promoter regions to ensure both universality and accuracy. For preclinical studies requiring higher precision, we also offer droplet digital PCR (ddPCR) to provide absolute quantification of viral titers.

Q3: Why does the AAV viral solution sometimes contain trace precipitates?

High-titer AAV preparations may exhibit slight aggregation when stored at 4°C or subjected to repeated freeze–thaw cycles due to high protein concentrations.

Recommendation: Upon receipt, immediately aliquot the virus according to single-use volumes and store at −80°C (stable for over one year). Prior to use, thaw on ice. If precipitates are observed, a brief low-speed centrifugation or gentle flicking of the tube should suffice.

Q4: How long after AAV transduction can expression be detected?

AAV is a single-stranded DNA virus that must convert to double-stranded DNA before transcription can begin. The uncoating process is relatively slow for non-enveloped viruses.

• In vitro (cell culture): Expression is typically detectable within 3–7 days.

• In vivo (animal studies): Peak expression is generally reached 2–4 weeks post-injection.

Certain serotypes or tissue types may require additional time for peak expression.

Q5: What are GeneRulor’s capabilities in AAV vector engineering?

Beyond standard packaging, GeneRulor offers advanced vector engineering services:

• Tissue-specific promoters: Including Syn (neuronal), cTnT (cardiomyocyte), and TBG (hepatic) promoters to minimize off-target expression.

• Cre-LoxP systems: DIO/FLEX constructs for conditional gene expression in defined cell populations.

• Stringent QC: In addition to titer determination, we provide empty capsid rate analysis (TEM negative staining or AUC), purity assessment (SDS-PAGE), and sterility and mycoplasma testing to ensure experimental reliability.

Q6: How should AAV virus be transported and stored?

Storage: For long-term storage, keep at −80°C (stable for over one year). At 4°C, storage should not exceed one week.

Shipping: All shipments are transported on dry ice with full cold-chain management and temperature monitoring to ensure viral activity is maintained throughout delivery.

References

[1] Wang, D., Tai, P.W.L., & Gao, G. (2019). Adeno-associated virus vector as a platform for gene therapy delivery. Nature Reviews Drug Discovery, 18, 358–378.

[2] Li, C., & Samulski, R.J. (2020). Engineering adeno-associated virus vectors for gene therapy. Nature Reviews Genetics, 21, 255–272.